Burrows Scott L — SEC insider filings

SEC reporting owner CIK 1853327. 25 insider filings on record with FilingPulse; latest filed 2026-10-02.

Transaction summary — filings shown

Covers all 25 filings on record, filed 2021-04-05 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Spyre Therapeutics, Inc. (SYRE)Chief Financial Officer16—28 legs · 147,691 sh · $9,945,93425
Arcutis Biotherapeutics, Inc. (ARQT)Chief Financial Officer9—8 legs · 15,424 sh · $298,5638

Insider filings — Burrows Scott L

FiledFormIssuerReported transactionsSource
2026-10-024Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 17,500 @ $14.50 · Sale (S): 17,500 @ $89.89 · Option exercise (M): 7,500 @ $14.50 · Sale (S): 600 @ $89.07 · Sale (S): 1,500 @ $90.27 · Sale (S): 2,100 @ $91.92 · +4 moreEDGAR
2026-09-034Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 7,500 @ $14.50 · Sale (S): 900 @ $86.25 · Sale (S): 4,384 @ $87.11 · Sale (S): 2,016 @ $88.03 · Sale (S): 200 @ $89.04 · Sale (S): 18,232 @ $89.35 · +1 moreEDGAR
2026-08-054Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 7,500 @ $14.50 · Sale (S): 5,100 @ $95.21 · Sale (S): 2,300 @ $96.30 · Sale (S): 100 @ $97.10 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2026-07-024Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 7,500 @ $14.50 · Sale (S): 5,775 @ $87.55 · Sale (S): 1,725 @ $88.37 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2026-06-264Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 15,000 @ $14.50 · Sale (S): 5,000 @ $87.12 · Sale (S): 10,000 @ $87.14 · Option exercise (M): 15,000 (derivative) @ $0EDGAR
2026-06-034Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 7,500 @ $14.50 · Sale (S): 1,801 @ $69.75 · Sale (S): 2,599 @ $70.77 · Sale (S): 3,100 @ $72.06 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2026-05-014Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 12,500 @ $14.50 · Sale (S): 12,500 @ $71.37 · Option exercise (M): 12,500 (derivative) @ $0EDGAR
2026-04-034Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 7,500 @ $14.50 · Sale (S): 6,200 @ $49.21 · Sale (S): 1,300 @ $49.98 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2026-03-034Spyre Therapeutics, Inc. (SYRE)Option exercise (M): 2,500 @ $14.50 · Sale (S): 2,300 @ $40.56 · Sale (S): 200 @ $41.66 · Option exercise (M): 2,500 (derivative) @ $0EDGAR
2026-01-134Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 140,000 (derivative) @ $0EDGAR
2025-09-034Spyre Therapeutics, Inc. (SYRE)Sale (S): 18,428 @ $16.26EDGAR
2025-01-174Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 95,500 (derivative) @ $0EDGAR
2024-09-054Spyre Therapeutics, Inc. (SYRE)Sale (S): 18,531 @ $28.17EDGAR
2024-02-024Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 70,000 (derivative) @ $0EDGAR
2023-12-224Spyre Therapeutics, Inc. (SYRE)Grant/award (A): 134,953 @ $0EDGAR
2023-09-054Aeglea BioTherapeutics, Inc. (AGLE)Grant/award (A): 10,121,441 (derivative) @ $0EDGAR
2023-03-084Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 291 @ $15.26EDGAR
2023-03-064Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 21,000 @ $0 · Grant/award (A): 55,800 (derivative) @ $0EDGAR
2023-03-024Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 416 @ $16.17 · Sale (S): 1,416 @ $15.82 · Sale (S): 18 @ $16.52EDGAR
2022-09-204Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 5,000 @ $1.68 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2022-03-074Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 13,300 @ $0 · Sale (S): 293 @ $16.86 · Sale (S): 10 @ $16.44 · Grant/award (A): 35,300 (derivative) @ $0EDGAR
2022-03-034Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 420 @ $17.75EDGAR
2022-01-044Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 55,704 (derivative) @ $0EDGAR
2021-12-284Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 12,560 @ $20.07EDGAR
2021-04-054Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 23,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-04-01 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1853327 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs